★ Analysts see FY2027 revenue reaching $1.3B — +42.0% growth in a single year.
What Moves the Stock
01Phase 2/3 clinical trial data readouts for lead programs (eplontersen cardiovascular outcomes, olezarsen triglyceride reduction, donidalorsen attack rate reduction)
02New partnership announcements with upfront payments and deal structures (recent deals average $150M-$400M upfront)
03FDA/EMA regulatory decisions and approval timelines for late-stage assets
04Spinraza royalty trends and competitive dynamics in SMA market (facing competition from Evrysdi and gene therapy)
05Pipeline expansion announcements and Investigational New Drug (IND) filings for novel targets
06R&D revenue from partnership collaborations (~60-70% of revenue, including upfront payments and milestone achievements from AstraZeneca, Biogen, Roche partnerships)
07Royalty revenue from commercialized products (~20-30%, primarily Spinraza royalties from Biogen partnership)
08Commercial product revenue (~5-10%, from wholly-owned products like Tegsedi and Waylivra in select markets)
growth - Attracts biotech specialists and growth investors focused on pipeline optionality rather than current earnings.
Rising interest rates negatively impact valuation through higher discount rates applied to long-dated cash flows (most pipeline value is…
Watch on earnings: Phase 3 trial enrollment rates and interim analysis timing for eplontersen, olezarsen, donidalorsen, Quarterly Spinraza global sales reported by Biogen (proxy for royalty revenue), New partnership deal announcements with upfront payment values and royalty tier structures.
One Sentence Summary:
Ionis Pharmaceuticals: the story is balanced — phase 2/3 clinical trial data readouts for lead programs (eplontersen cardiovascular outcomes, olezarsen triglyceride reduction.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
